About US
Contact us
-
US firm twoXAR and Stanford University partner to identify drug candidates for HCCUS-based twoXAR has collaborated with Stanford University School of Medicine’s Asian Liver Centre, in a bid to support research for identifying drug candidates targeting hepatocellular carcinoma (HCC)2016/9/8
-
Sun Pharma forms distribution partnership with Mitsubishi Tanabe in JapanSun Pharma has formed a distribution partnership with Mitsubishi Tanabe Pharma Corporation in Japan for the 14prescription brands acquired from Novartis. The movemarks the initiation of a phased tran2016/9/7
-
Takeda to develop vaccine to support Zika response in USThe US Biomedical Advanced Research and Development Authority (BARDA) has selected Japanese company Takeda Pharmaceutical’s Vaccine Business Unit to develop a vaccine to support the Zika response with2016/9/7
-
Biogen’s investigational treatment Aducanumab secures FDA fast-track designationBiogen’s investigational treatment Aducanumab for early Alzheimer’s disease (AD) has secured fast-track designation from the US Food and Drug Administration (FDA). The programme will support the deve2016/9/6
-
FDA approves Amgen’s sBLA for leukaemia drug BlincytoThe US Food and Drug Administration (FDA) has approved Amgen’s supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data that supports the treatment of pediatri2016/9/6
-
Deals this week: Elite Pharmaceuticals, Orexigen Therapeutics, LegoChem BiosciencesElite Pharmaceuticalsand SunGen Pharma LLC have entered a development and licensing agreement for four generic pharmaceutical products. According to the agreement, the two partners will share the cos2016/9/5
-
M&As this week: Sichuan Kelun Pharmaceutical Co. and Avantor Performance MaterialsSichuan Kelun Pharmaceutical Co. has announced plans to acquire the remaining 15% stake in Zhejiang-based pharmaceutical unit for ¥65.3m ($9.78m). "Avantor Performance Materials has announced pla2016/9/5
-
Amgen's plan for a speedy launch of Repatha in India hits the skidsAmgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead. The U.S. biotech was aiming toimport and marketRep2016/9/2
-
Boehringer's Pradaxa keeps its antidote edge as FDA swats down Portola contenderLast year, Boehringer Ingelheim’s Pradaxa picked up an edge on its new-age anticoagulant rivals when the FDA approved a reversal agent. Now, the agency has turned back an antidote to blockbuster rival2016/9/2
-
Ex-Insys salespeople plead not guilty in Subsys kickbacks schemeTwo former Insys Therapeutics salespeople indicted in a kickback scheme pleaded not guilty in Manhattan federal court Wednesday. The two are the latest ex-Insys staffers to run afoul of a federal prob2016/9/1